Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries has received approval from the FDA for its abbreviated new drug application for Ondansetron hydrochloride Injection USP, 2mg/mL.
Subscribe to our email newsletter
Taro’s Ondansetron Injection is used for the prevention of nausea and vomiting associated with chemotherapy. This new Taro sterile injectable prescription product is bioequivalent to GlaxoSmithKline’s Zofran Injection, 2mg/mL. Taro’s Ondansetron Injection will be manufactured in the company’s sterile facility in Ireland.